Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Protagonist Therapeutics
Protagonist Therapeutics
Takeda grabs late-stage hematology drug from Protagonist
Pharmaphorum
Thu, 02/1/24 - 11:20 am
Takeda
hematology
Protagonist Therapeutics
polycythemia vera
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Biotechs put assets up for sale and on the shelf in quarterly pipeline clear-outs
Fierce Biotech
Wed, 11/9/22 - 10:53 am
Xilio Therapeutics
Protagonist Therapeutics
Arbutus BioPharma
Aptinyx
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis
Fierce Biotech
Tue, 04/26/22 - 10:16 am
Protagonist Therapeutics
clinical trials
ulcerative colitis
Entyvio
Protagonist seeks an Ideal readout
EP Vantage
Wed, 04/6/22 - 11:37 am
Protagonist Therapeutics
PN-943
clinical trials
ulcerative colitis
Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload disease
Fierce Biotech
Mon, 11/15/21 - 10:59 am
Protagonist Therapeutics
clinical trials
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Yahoo Finance
Mon, 10/11/21 - 10:25 am
Protagonist Therapeutics
clinical trials
FDA
rusfertide
polycythemia
FDA hits pause on Protagonist's blood cancer med after mouse study turns up skin tumors
Fierce Biotech
Sat, 09/18/21 - 08:21 pm
Protagonist Therapeutics
clinical trials
blood cancer
FDA
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
Tue, 05/30/17 - 06:20 pm
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
5 Biotech IPOs Lead The Way In 2016
Seeking Alpha
Mon, 11/28/16 - 09:51 am
biotech
IPOs
AveXis
Clearside Biomedical
Protagonist Therapeutics
Reata Pharmaceuticals
Bluebird Bio
Protagonist Therapeutics, Ironwood sign peptide drug deal
Bizjournals.com
Wed, 01/19/11 - 10:32 am
peptides
Protagonist Therapeutics
Ironwood